Recombinant Anti-C9 antibody [EPR11232-82] (ab173302)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR11232-82] to C9
- Suitable for: WB, IHC-P
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-C9 antibody [EPR11232-82]
See all C9 primary antibodies -
Description
Rabbit monoclonal [EPR11232-82] to C9 -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-Pmore details
Unsuitable for: IP -
Species reactivity
Reacts with: Human
Does not react with: Mouse, Rat -
Immunogen
Recombinant fragment within Human Complement C9. The exact sequence is proprietary.
Database link: P02748 -
Positive control
- WB: Human serum lysates; IHC-P: human colon and spleen tissue.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR11232-82 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab173302 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000 - 1/10000. Detects a band of approximately 72 kDa (predicted molecular weight: 63 kDa).
|
|
IHC-P |
1/10000. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
See IHC antigen retrieval protocols. For unpurified use at 1/100 - 1/200. |
Notes |
---|
WB
1/1000 - 1/10000. Detects a band of approximately 72 kDa (predicted molecular weight: 63 kDa). |
IHC-P
1/10000. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. See IHC antigen retrieval protocols. For unpurified use at 1/100 - 1/200. |
Target
-
Function
Constituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells. C9 is the pore-forming subunit of the MAC. -
Tissue specificity
Plasma. -
Involvement in disease
Defects in C9 are a cause of complement component 9 deficiency (C9D) [MIM:613825]. A rare defect of the complement classical pathway associated with susceptibility to severe recurrent infections, predominantly by Neisseria gonorrhoeae or Neisseria meningitidis. -
Sequence similarities
Belongs to the complement C6/C7/C8/C9 family.
Contains 1 EGF-like domain.
Contains 1 LDL-receptor class A domain.
Contains 1 MACPF domain.
Contains 1 TSP type-1 domain. -
Post-translational
modificationsThrombin cleaves factor C9 to produce C9a and C9b.
Phosphorylation sites are present in the extracelllular medium. -
Cellular localization
Secreted. Cell membrane. Secreted as soluble monomer. Oligomerizes at target membranes, forming a pre-pore. A conformation change then leads to the formation of a 100 Angstrom diameter pore. - Information by UniProt
-
Database links
- Entrez Gene: 735 Human
- Omim: 120940 Human
- SwissProt: P02748 Human
- Unigene: 654443 Human
-
Alternative names
- ARMD15 antibody
- C9 antibody
- C9 deficiency antibody
see all
Images
-
Anti-C9 antibody [EPR11232-82] (ab173302) at 1/10000 dilution (Purified) + Human serum lysates at 15 µg
Secondary
Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution
Predicted band size: 63 kDa
Observed band size: 60-70 kDa why is the actual band size different from the predicted?The molecular weight observed is consistent with what has been described in PMID: 29767720
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Complement C9 antibody [EPR11232-82] (ab173302)
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human colon tissue sections labeling Complement C9 with purified ab173302 at 1/10,000 dilution (0.07 µg/ml). Heat mediated antigen retrieval was performed using ab93684 (Tris/EDTA buffer, pH 9.0). ImmunoHistoProbe one step HRP Polymer (ready to use) was used as the secondary antibody. Negative control: PBS instead of the primary antibody. Hematoxylin was used as a counterstain.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Complement C9 antibody [EPR11232-82] (ab173302)
Immunohistochemical analysis of paraffin embedded Human colon tissue labeling Complement C9 with ab173302 (unpurified) at 1/100.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-Complement C9 antibody [EPR11232-82] (ab173302)
Immunohistochemical analysis of paraffin embedded Human spleen tissue labeling Complement C9 with ab173302 (unpurified) at 1/100.
Protocols
Datasheets and documents
-
Datasheet download
References (6)
ab173302 has been referenced in 6 publications.
- Zhao L et al. Solidified glomerulosclerosis, identified using single glomerular proteomics, predicts end-stage renal disease in Chinese patients with type 2 diabetes. Sci Rep 11:4658 (2021). PubMed: 33633132
- D'Agnillo F et al. Structural Integrity of the Alveolar-Capillary Barrier in Cynomolgus Monkeys Challenged with Fully Virulent and Toxin-Deficient Strains of Bacillus anthracis. Am J Pathol 190:2095-2110 (2020). PubMed: 32598882
- Chantaraamporn J et al. Glycoproteomic Analysis Reveals Aberrant Expression of Complement C9 and Fibronectin in the Plasma of Patients with Colorectal Cancer. Proteomes 8:N/A (2020). PubMed: 32971853
- Deleon-Pennell KY et al. Glycoproteomic Profiling Provides Candidate Myocardial Infarction Predictors of Later Progression to Heart Failure. ACS Omega 4:1272-1280 (2019). PubMed: 30729226
- Zhao P et al. The imbalance in the complement system and its possible physiological mechanisms in patients with lung cancer. BMC Cancer 19:201 (2019). PubMed: 30841875
- Tougan T et al. Molecular Camouflage of Plasmodium falciparum Merozoites by Binding of Host Vitronectin to P47 Fragment of SERA5. Sci Rep 8:5052 (2018). PubMed: 29567995